Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

Article Category

Article available in the following languages:

Preventing inherited cancers before they start

Early genetic testing and preventive care could improve outcomes for people with inherited cancer risks. Emerging evidence indicates that prevention is less costly.

Imagine knowing that you are at least 50 times more likely to develop an aggressive, early-onset cancer than other people in your community. This is the reality for people with rare tumour risk syndromes (RTRS), inherited conditions that affect fewer than five in every 10 000 people. When a hereditary cancer risk is identified in one family member, it raises a flag that their relatives may also carry the same genetic variant. Those who test positive can be offered surveillance and, where appropriate, preventive interventions before cancer develops. However, healthcare systems often remain focused on treating cancer after it appears. Demonstrating the clinical and economic benefits of proactive care is therefore essential to change this approach.

A proactive approach to cancer

The key objective of the EU-funded PREVENTABLE(opens in new window) project was to evaluate whether proactive surveillance offers advantages over waiting until cancer develops. The project’s analysis compared the costs and outcomes of prevention pathways with those of treating early and advanced disease, including the cumulative costs of care over time. “Prevention should not be viewed as an additional expense, but as an investment in better health outcomes,” emphasises the project coordinator Carla Oliveira. PREVENTABLE brought together clinical teams, scientists, health economists, social scientists healthcare managers and communication and outreach specialists. Nine European reference centres within the European Reference Network GENTURIS(opens in new window) mapped care pathways for eight RTRS, covering genetic testing, surveillance, preventive surgery and treatment options. These pathways were validated using real-world clinical data and hospital costs, incorporating the evidence into health economic models. Project findings(opens in new window) indicate that treatment pathways can incur higher costs per patient, driven partly by a small number of expensive interventions. Prevention involves planned, recurring procedures, which can detect precancerous lesions or cancers at an earlier, more treatable stage. The project also found that proactive prevention improves overall survival, strengthening the case for integrating these pathways into routine healthcare.

Insight into patient experience

The consortium examined not only whether prevention works but also how patients and families perceive it. Behavioural research(opens in new window) identified communication barriers and difficulties associated with discussing genetic diagnoses with relatives, alongside gaps in social support. “Effective prevention depends on more than clinical recommendations. People need understandable information, support in communicating genetic risk within their families and healthcare professionals equipped to guide difficult decisions,” explains Oliveira. PREVENTABLE’s findings informed recommendations for improving communication between patients and healthcare teams. The project also created a freely accessible RTRS Learning Hub(opens in new window) featuring real-life stories, documentaries and infographics for patients, professionals and the wider public.

Turning evidence into routine care

Despite the potential benefits, access to prevention remains uneven. Hospitals may lack comprehensive guidelines, coordinated services and sufficient staff for surveillance programmes. Fragmented care, reimbursement difficulties and limited recognition of specialist reference centres can also hinder implementation. To support more consistent care, PREVENTABLE developed recommendations and information management tools. “By showing the costs, workforce requirements and health benefits of prevention, we can help decision-makers move from reactive cancer treatment towards risk-based care,” highlights Oliveira. Wider adoption will require sustained policy support and investment in specialist services. For families affected by inherited tumour risk, the goal is to make a genetic diagnosis a starting point for informed prevention, rather than a prediction of inevitable cancer.

Discover other articles in the same domain of application